U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.

from Health and Science https://ift.tt/yVkNL86
https://ift.tt/dGxtNaz
https://ift.tt/eufVwyj